Table 4 Univariate analysis for overall survival
Characteristic | OS, month (95% CI) | HR (95% CI) | P-value | HRa (95% CI) | P-valuea |
|---|---|---|---|---|---|
Age, years | 2.03 (0.99–4.14) | 0.051 | 3.71 (1.00–13.79) | 0.050 | |
< 61 | 29.5 (28.6-NR) | ||||
≥ 61 | 25.4 (18.7–41.3) | ||||
Gender | 0.88 (0.41–1.61) | 0.555 | 0.74 (0.36–2.35) | 0.616 | |
Female | 29.5 (25.2-NR) | ||||
Male | 29.5 (18.7-NR) | ||||
ECOG PS | 1.62 (0.66–3.99) | 0.297 | 1.19 (0.36–5.47) | 0.821 | |
0–1 | 29.5 (25.2–41.3) | ||||
≥ 2 | 26.4 (15.4-NR) | ||||
Tumor location | 0.91 (0.59–1.35) | 0.588 | 1.21 (0.59–2.48) | 0.599 | |
Right lung | 28.8 (22.3-NR) | ||||
Left lung | 29.5 (23.8-NR) | ||||
Right + left | 29.5 (17.6-NR) | ||||
Tumor size at baseline (cm) | 0.75 (0.47–1.14) | 0.171 | 0.82 (0.42–1.21) | 0.257 | |
≤ 3 | 26.2 (11.5–29.5) | ||||
> 3–5 | 26.7 (23.8-NR) | ||||
> 5 | 29.5 (22.3-NR) | ||||
M-Staging | 1.72 (0.99–3.01) | 0.056 | 1.04 (0.50–2.65) | 0.942 | |
M0 | NR (16.0-NR) | ||||
M1a | NR (25.2-NR) | ||||
M1b | 25.4 (21.8–39.1) | ||||
Brain metastasis at baseline | 1.12 (0.53–2.37) | 0.759 | 0.79 (0.41–1.93) | 0.371 | |
No | 29.5 (23.8-NR) | ||||
Yes | 28.6 (19.7–37.2) | ||||
Bone metastasis at baseline | 2.46 (1.22–4.94) | 0.011 | 2.23 (0.91–7.06) | 0.121 | |
No | 29.5 (25.8-NR) | ||||
Yes | 25.4 (18.7-NR) | ||||
Liver metastasis at baseline | 1.55 (0.71–3.36) | 0.267 | 1.62 (0.44–6.01) | 0.469 | |
No | 29.5 (25.2-NR) | ||||
Yes | 25.4 (18.7-NR) | ||||
Pleural effusion at baseline | 0.92 (0.44–1.93) | 0.825 | 0.97 (0.45–3.27) | 0.965 | |
No | 29.7 (23.8-NR) | ||||
Yes | 25.8 (23.8-NR) | ||||
EGFR mutation type | 1.50 (0.75–2.98) | 0.247 | 1.26 (0.39–4.01) | 0.693 | |
E19del | 28.9 (23.8-NR) | ||||
L858R | 25.8 (19.7–29.5) | ||||
EGFR plasma at baseline | 8.18 (2.06–32.49) | < 0.001 | 5.69 (1.48–21.95) | 0.011 | |
Negative | NR (21.3-NR) | ||||
Positive | 18.3 (15.0-NR) | ||||
Unknown | 29.5 (25.2-NR) | ||||
Treatment method | 1.69 (1.12–2.61) | 0.016 | 2.61 (1.09–6.38) | 0.033 | |
TKI alone | 25.2 (18.3-NR) | ||||
TKI + Che/Ra | 28.6 (18.7-NR) | ||||
TKI + Sur | NR (25.8-NR) | ||||
Brain metastasis after treatment | 2.33 (1.08–5.05) | 0.032 | 1.73 (0.66–6.45) | 0.411 | |
No | 29.5 (25.2-NR) | ||||
Yes | 22.3 (8.9-NR) | ||||
Bone metastasis after treatment | 2.78 (1.40–5.54) | 0.003 | 1.74 (0.53–5.77) | 0.363 | |
No | NR (25.8-NR) | ||||
Yes | 23.8 (18.3–29.5) | ||||
Liver metastasis after treatment | 2.01 (0.97–4.17) | 0.059 | 1.14 (0.35–3.67) | 0.831 | |
No | 34.9 (25.4-NR) | ||||
Yes | 23.8 (18.3-NR) | ||||
Pleural effusion after treatment | 1.16 (0.56–2.39) | 0.686 | 0.71 (0.33–2.71) | 0.488 | |
No | 29.4 (25.4-NR) | ||||
Yes | 25.2 (21.8-NR) | ||||
New metastasis site | 3.59 (1.76–7.33) | < 0.001 | 2.11 (0.98–6.69) | 0.052 | |
No | NR (25.8-NR) | ||||
Yes | 22.3 (18.3–28.6) | ||||
EGFR plasma after treatment | 2.66 (1.10–6.45) | 0.031 | 3.37 (0.96–10.34) | 0.059 | |
Negative | NR (29.5-NR) | ||||
Positive | 25.2 (21.8–35.9) | ||||
Secondary T790M | 1.41 (0.70–2.83) | 0.342 | 3.64 (1.02–12.96) | 0.047 | |
Negative | 29.5 (25.2-NR) | ||||
Positive | 25.8 (17.6-NR) | ||||
CfDNA (ng/mL) | 2.34 (1.15–4.80) | 0.019 | 6.27 (1.85–21.24) | 0.003 | |
≤ 200 | NR (23.8-NR) | ||||
> 200 | 25.8 (17.6-NR) | ||||